Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung Cancer

18 Oct 2024

Abstract excerpt

Non-small cell lung cancer (NSCLC) remains a disease with a poor prognosis despite the advances in therapies. NSCLC with actionable oncogenic alterations represent a subgroup of diseases for which tyrosine kinase inhibitors (TKIs) have shown relevant and robust impact on prognosis, both in early and advanced stages. While the introduction of powerful TKIs increases the ratio of potentially curable patients, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39456995
DOI: 10.3390/ijms252011214

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung CancerPMID 39456995Read ↗

Proteolysis targeting chimeras in non-small cell lung cancer.Semantic proximity Read ↗

[Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy].Semantic proximity Read ↗

Overcoming Cancer Drug Resistance Utilizing PROTAC TechnologySemantic proximity Read ↗

Targeted Protein Degradation in Lung Cancer: The Emerging Role of PROTAC Technology and E3 LigasesSemantic proximity Read ↗

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapySemantic proximity Read ↗

Targeting the Interplay of Proteins through PROTACs for the Management of Cancer and Associated DisordersSemantic proximity Read ↗

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?Semantic proximity Read ↗

Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins.Semantic proximity Read ↗

Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?Semantic proximity Read ↗

Effective degradation of EGFRL858R+T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy/lysosome degradation systems.Semantic proximity Read ↗

Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.Semantic proximity Read ↗

Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.